Carole Faig
Director/Board Member at HENRY SCHEIN, INC.
Net worth: 198 463 $ as of 29/04/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Ronald South | M | 62 | 16 years | |
Michael Ettinger | M | 63 | 30 years | |
Stanley Bergman | M | 74 | 44 years | |
Reed Tuckson | M | 73 | 3 years | |
Kelly Murphy | F | 43 | 13 years | |
Anne Margulies | F | 68 | 6 years | |
Talha Ashraf | M | - |
QuVa Pharma, Inc.
QuVa Pharma, Inc. Pharmaceuticals: MajorHealth Technology QuVa Pharma, Inc. provides sterile compounding pharmacy services. It develops, manufactures and distributes compounded sterile preparations. The firm provides vital compounded medications for obstetrics, OR, anesthesia, general medicine, cardiovascular, ER, and pain management. The company was founded by Stuart Hinchen and Peter Linsay Jenkins in 2015 and is headquartered in Austin, TX. | 3 years |
Caroline Stout | F | 33 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 3 years |
Philip Laskaway | M | 82 | 22 years | |
Rick Modi | M | 55 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 5 years |
Jennifer Ferrero | F | - | - | |
Mohamad Ali | M | 53 | 3 years | |
Stuart Hinchen | M | - |
QuVa Pharma, Inc.
QuVa Pharma, Inc. Pharmaceuticals: MajorHealth Technology QuVa Pharma, Inc. provides sterile compounding pharmacy services. It develops, manufactures and distributes compounded sterile preparations. The firm provides vital compounded medications for obstetrics, OR, anesthesia, general medicine, cardiovascular, ER, and pain management. The company was founded by Stuart Hinchen and Peter Linsay Jenkins in 2015 and is headquartered in Austin, TX. | 9 years |
Luk Vandenberghe | M | 47 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 5 years |
Scott Serota | M | 67 | 3 years | |
Peter Linsay Jenkins | M | - |
QuVa Pharma, Inc.
QuVa Pharma, Inc. Pharmaceuticals: MajorHealth Technology QuVa Pharma, Inc. provides sterile compounding pharmacy services. It develops, manufactures and distributes compounded sterile preparations. The firm provides vital compounded medications for obstetrics, OR, anesthesia, general medicine, cardiovascular, ER, and pain management. The company was founded by Stuart Hinchen and Peter Linsay Jenkins in 2015 and is headquartered in Austin, TX. | 9 years |
Dave Grayzel | M | 56 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 4 years |
Ed Mathers Mathers | M | 64 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 4 years |
Sean Nolan | M | 56 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 5 years |
Michael Racioppi | M | 69 | 32 years | |
Mark Mlotek | M | 68 | 30 years | |
Deborah Derby | F | 60 | 3 years | |
Joseph Herring | M | 68 | 8 years | |
Bradley Sheares | M | 67 | 14 years | |
Carol Raphael | F | 81 | 12 years | |
Walter Siegel | M | 65 | 11 years | |
Charles Sigal | M | 72 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 4 years |
Kurt Kuehn | M | 69 | 8 years | |
Trinh Clark | F | - | - | |
Olga Timoshkina | F | - | 3 years | |
Bradford Connett | M | - | 3 years | |
Leigh Benowitz | F | - | - | |
Aaron Tward | M | - |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 5 years |
Laura Richman | M | 60 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 4 years |
Petra Kaufmann | M | 58 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 3 years |
Rob Aboud | M | 59 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 5 years |
Robert May | M | 56 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 4 years |
Michael Amodio | M | - | - | |
Reid Arstark | M | - | 3 years | |
Scott Aladeen | M | - |
QuVa Pharma, Inc.
QuVa Pharma, Inc. Pharmaceuticals: MajorHealth Technology QuVa Pharma, Inc. provides sterile compounding pharmacy services. It develops, manufactures and distributes compounded sterile preparations. The firm provides vital compounded medications for obstetrics, OR, anesthesia, general medicine, cardiovascular, ER, and pain management. The company was founded by Stuart Hinchen and Peter Linsay Jenkins in 2015 and is headquartered in Austin, TX. | 3 years |
Paula Cobb | F | 51 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 4 years |
Diana Brainard | M | 53 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 2 years |
Graham Barry Stanley | M | 56 | 20 years | |
Randall McLemore | M | - | - | |
Christopher Pendergast | M | 61 | 6 years | |
Charles Albright | M | 66 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 3 years |
Ann Marie Gothard | F | - | 8 years | |
Steven W. Kess | M | - | 33 years | |
Stefanie Fleige | F | - | - | |
Botond Roska | M | 54 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 5 years |
Andrew T. Kaplan | M | 39 |
QuVa Pharma, Inc.
QuVa Pharma, Inc. Pharmaceuticals: MajorHealth Technology QuVa Pharma, Inc. provides sterile compounding pharmacy services. It develops, manufactures and distributes compounded sterile preparations. The firm provides vital compounded medications for obstetrics, OR, anesthesia, general medicine, cardiovascular, ER, and pain management. The company was founded by Stuart Hinchen and Peter Linsay Jenkins in 2015 and is headquartered in Austin, TX. | 9 years |
Gerard K. Meuchner | M | - | 12 years | |
Lorelei McGlynn | F | 60 | 25 years | |
Mark Hillebrandt | M | - | 6 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Ayub Khattak | M | 39 | 14 years | |
Steven Paladino | M | 66 | 37 years | |
Clint Sever | M | 39 | 14 years | |
Rishi Reddy | M | - | - | |
Joshua Ghaim | M | 56 | 2 years | |
Erica Palsis | F | 38 | 2 years | |
Sachin Jain | M | 43 | 2 years | |
James Breslawski | M | 70 | 44 years | |
Scott Stanford | M | 54 | 5 years | |
Randall Pollard | M | 52 | 2 years | |
Aasim Javed | M | 40 | 3 years | |
Chris Achar | M | 39 | 6 years | |
Joanne Bradford | F | 60 | 3 years | |
Maria Martinez | F | 66 | 3 years | |
Ming Hui Gao | M | 51 | 3 years | |
Suzanne Stone | F | - | 1 years | |
David Tsay | M | - | 2 years | |
Andy Hudak | M | - | 3 years | |
Elizabeth Swanson | F | - | - | |
Nitin Duggal | M | - | 3 years | |
Asish Xavier | M | - | 1 years | |
David Arida | M | - | 2 years | |
Xiang Ming Cui | M | 55 | 2 years | |
Glenn Wada | M | - | - | |
Thomas Leggett | M | 47 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 3 years |
Alan Gao | M | - | - | |
John Gallagher | M | 51 | 2 years | |
Allison F. Blackwell | F | 59 | 2 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 82 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Carole Faig
- Personal Network